Page 49 - Read Online
P. 49
Page 334 Genvigir et al. J Transl Genet Genom 2020;4:320-55 I http://dx.doi.org/10.20517/jtgg.2020.37
Ref. [14] [34] [40] [13] [63] [37] [66] [29]
Clinical outcomes No association of ABCC2 c.-24C>T and c.3972C>T variants with gastrointestinal adverse No association of ABCC2 c.-24C>T, c.1249G>A, 1446C>G and c.3972C>T variants with AR or adverse events No association of ABCC2 c.-24C>T, c.1249G>A, c.3972C>T and c.4544G>A variants with AR or adverse events
- events -
Pharmacokinetics No association of ABCC2 c.-24C>T variant with MPA or MPAG pharmacokinetics - No association of ABCC2 - c.-24C>T, c.1249G>A, 3563T>A and c.3972C>T variants with MPA pharmacokinetics - ABCC2 c.-24T allele was associated with lower MPA AUC, on cyclosporine-free treatment No association of ABCC2 - c.-24T variant with MPA or MPAG exposure (AUC 4-12 or AUC 0-12 ) No association of ABCC2 - c.-24C>T and c.3972C>T vari
Immunosuppressive regimen MMF Cyclosporine Tacrolimus Sirolimus Corticosteroids At a point between 3-6 months MMF Cyclosporine Tacrolimus Sirolimus Up to 115-month follow- up MMF Cyclosporine Tacrolimus Corticosteroids Sixty-day follow-up MMF Cyclosporine Tacrolimus mTOR inhibitor Corticosteroids One-year follow-up MMF Cyclosporine Tacrolimus Sirolimus Corticosteroids Three-month follow-up MMF Cyclosporine Prednisone MMF Cyc
Population 256 adult patients 89 pediatric patients
185 patients (France) (France) (France) (France) 55 adult patients (Spain) 37 adult patients (China) 56 adult patients 189 adult patients (France)
Study design Prospective (included multicenter Apomygre study) Retrospective Prospective, multicenter Retrospective (Transgene 218 adult patients study) Prospective, multicenter (Symphony study) Prospective, Multicenter (Case-control) Prospective, multicenter (Symphony study) Prospective, multicenter (Dominos study)
Allele frequency c.-24T: 23% c.-24T: 24% c.3972T: 39% c.-24T:19% c.1249A: 19% 3563A: 10% c.3972T:35% c.-24T: 19% c.1249A: 19% 1446G: 0.7% c.3972T: 35% c.-24T: 21% c.3972T: 23% c.-24T: 28% c.-24T: 19% c.3972T: 36% c.-24T: 17% c.1249A: 21% c.3972T: 39% c.4544A: 8%
Variant
Gene